Form 4: Amgen EVP David M. Reese Reports Stock and Option Awards

David M. Reese, EVP & Chief Technology Officer of Amgen, reports the acquisition of stock and option awards.

Summary

• On May 7, 2024, David M. Reese, EVP & Chief Technology Officer of Amgen, reported transactions related to Amgen stock.
• Reese acquired 3,196 shares of common stock through Restricted Stock Units (RSUs) and 20,767 non-qualified stock options.
• The RSUs vest in three annual installments starting May 7, 2026, and the stock options are exercisable in three installments beginning the same date.
• Following these transactions, Reese beneficially owns 61,889 shares of Amgen common stock, including previously granted RSUs and Dividend Equivalents (DEs).

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation. It's neither particularly positive nor negative, but reflects standard corporate governance practices.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Technology Officer suggests the company is incentivizing long-term performance and retention.
• The vesting schedules for both RSUs and stock options are spread over multiple years, aligning executive compensation with sustained value creation.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and options suggests a multi-year commitment from the executive.

Industry Context

Stock and option awards are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. The vesting schedules are typical for such awards.

Comparison to Industry Standards

• Amgen's equity compensation practices are broadly in line with industry standards for large-cap biotechnology companies.
• Companies like Gilead Sciences, Biogen, and Regeneron also utilize stock options and restricted stock units as key components of executive compensation packages.
• Vesting schedules of three to four years are common to ensure long-term alignment and retention.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign that management's interests are aligned with theirs.
• Employees may see the grants as a reflection of the company's commitment to rewarding key personnel.

Key Dates